Description  Claims  Drawing  Cited references 

US61169031A   [0001] 

Mechanism of action of tetanus and botulinum neurotoxins   [0072] 
Mode of action of botulinum neurotoxin: pathological, cellular and molecular aspect   [0072] 
Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells   [0072] 
SV2 is the protein receptor for botulinum neurotoxin A   [0072] 
Synaptotagmins I and II act as nerve cell receptors for botulinum neurotoxin G   [0072] 
Structure and function of SNARE and SNARE-interacting proteins   [0072] 
SNAP-23 is not cleaved by botulinum neurotoxin E and can replace SNAP-25 in the process of insulin secretion   [0072] 
Proteolysis of SNAP-25 isoforms by botulinum neurotoxin types A, C, and E: domains and amino acid residues controlling the formation of enzyme-substrate complexes and cleavage   [0072] 
SNAREs--engines for membrane fusion   [0072] 
Botulinum toxin: From life-threatening disease to novel medical therapy   [0072] 
Botulinum toxin: from life-threatening disease to novel medical therapy   [0072] 
Review of the use of botulinum toxin for hyperhidrosis and cosmetic purposes   [0072] 
Unlabeled uses of botulinum toxins: a review   [0072] 
Retargeted clostridial endopeptidases: inhibition of nociceptive neurotransmitter release in vitro, and antinociceptive activity in in vivo models of pain   [0072] 
Inhibition of release of neurotransmitters from rat dorsal root ganglia by a novel conjugate of a Clostridium botulinum toxin A endopeptidase fragment and Erythrina cristagalli lectin   [0072] 
Re-engineering the target specificity of Clostridial neurotoxins - a route to novel therapeutics   [0072] 
Regulated airway goblet cell mucin secretion   [0072] 
Physiology of airway mucus secretion and pathophysiology of hypersecretion   [0072] 
Multiple pocket recognition ofSNAP25 by botulinum neurotoxin serotype E   [0072] 
Unique substrate recognition by botulinum neurotoxins serotypes A and E   [0072] 
Substrate recognition mechanism of V AMP/synaptobrevin-cleaving clostridial neurotoxins   [0072] 
Substrate recognition ofVAMP-2 by botulinum neurotoxin B and tetanus neurotoxin   [0072] 
The identification of a novel synaptosomal-associated protein, SNAP-25, differentially expressed by neuronal subpopulations   [0072] 
Identification of SNAP-47, a novel Qbc-SNARE with ubiquitous expression   [0072] 
SNAP-29-mediated modulation of synaptic transmission in cultured hippocampal neurons   [0072] 
SNAP-23 is not essential for constitutive exocytosis in HeLa cells   [0072] 
Syntaxin 2 and SNAP-23 are required for regulated surfactant secretion   [0072] 
Involvement of SNAP-23 and syntaxin 6 in human neutrophil exocytosis   [0072] 
The t-SNARE syntaxin 4 is regulated during macrophage activation to function in membrane traffic and cytokine secretion   [0072] 
Immunotoxins and cytokine toxin fusion proteins   [0072]  [0072] 
New immunotoxins targeting CD123, a stem cell antigen on acute myeloid leukemia cells   [0072]  [0072] 
Association of botulinum neurotoxin serotypes A and B with synaptic vesicle protein complexes   [0072] 
Cysteine residues of SNAP-25 are required for SNARE disassembly and exocytosis, but not for membrane targeting   [0072] 
Humanized antibodies   [0072] 
Humanization of chicken monoclonal antibody using phage-display system   [0072] 
Protective antigen-binding domain of anthrax lethal factor mediates translocation of a heterologous protein fused to its amino- or carboxy-terminus   [0072] 
Drug Deliv.   [0072] 
Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee   [0072] 
Engineering botulinum neurotoxin to extend therapeutic intervention   [0072] 
Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia   [0072] 
Novel therapeutic nano-particles (lipocores): trapping poorly water soluble compounds   [0072]